Aurobindo To Formalize Succession Plan In Dec As MD Readies Exit
Vaxxinity COVID-19 Vaccine Plans Hit Roadblock
Executive Summary
Aurobindo will formalize a succession plan in early December as managing director N Govindarajan, who has spent over a decade at the company, is set to move on. Meanwhile, though a settlement has been reached for generic Revlimid launch plans, development of a COVID-19 vaccine with partner Vaxxinity has hit a major roadblock
You may also be interested in...
CEO Pay Mostly Up In India In Year Of C-Suite Exits
Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.
Torrent Settles With BMS For Revlimid, Launch Timeline Undisclosed
Torrent has reached a settlement with BMS’ Celgene over oncology blockbuster Revlimid, officials said during a Q2 call, but declined to disclose launch timelines for the generic. Meanwhile, the Indian company continues to evaluate an option to enter the injectables segment in the US as revenues slide.
Aurobindo Files First Biosimilar In Europe With Pegfilgrastim
Aurobindo has submitted its first biosimilar application to the EMA, with the Indian company’s CuraTeQ subsidiary filing its BP14 pegfilgrastim rival to Neulasta.